Hormone Responsive Cancers (HRC)

$38,032P30FY2018CANIH

University Of Maryland Baltimore, Baltimore MD

Investigators

Linked publications & trials

Paper 39650739 Paper 39605639 Paper 39484607 Paper 39363741 Paper 39317013 Paper 39281872 Paper 39264110 Paper 39235855 Paper 39207518 Paper 39195240 Paper 39185519 Paper 39167663 Paper 39105866 Paper 39078314 Paper 39052835 Paper 38990731 Paper 38923793 Paper 38915559 Paper 38862755 Paper 38849082 Paper 38739710 Paper 38547441 Paper 38543121 Paper 38492853 Paper 38481255 Paper 38442593 Paper 38429897 Paper 38385273 Paper 38370665 Paper 38349430 Paper 38340107 Paper 38330941 Paper 38284896 Paper 38281073 Paper 38270539 Paper 38200081 Paper 38193117 Paper 38157646 Paper 38102143 Paper 38092472 Paper 38070689 Paper 38069666 Paper 37999712 Paper 37938184 Paper 37919335 Paper 37908366 Paper 37872047 Paper 37838697 Paper 37812336 Paper 37770478 Paper 37768050 Paper 37751207 Paper 37737895 Paper 37737303 Paper 37685837 Paper 37675514 Paper 37625737 Paper 37619561 Paper 37467316 Paper 37292609 Paper 37290827 Paper 37278257 Paper 37277479 Paper 37227250 Paper 37219857 Paper 37174666 Paper 37122730 Paper 37121401 Paper 37092548 Paper 37066185 Paper 37060364 Paper 37053110 Paper 37042657 Paper 37018922 Paper 36966496 Paper 36877839 Paper 36833323 Paper 36826509 Paper 36822786 Paper 36727462 Paper 36642094 Paper 36536390 Paper 36534160 Paper 36525379 Paper 36285644 Paper 36078112 Paper 35938721 Paper 35922099 Paper 35867758 Paper 35848131 Paper 35775481 Paper 35759659 Paper 35726480 Paper 35717688 Paper 35681619 Paper 35671122 Paper 35667295 Paper 35655862 Paper 35652591 Paper 35603904

Abstract

16.0 Abstract: Hormone Responsive Cancers Program The overarching goal of the Hormone Responsive Cancers (HRC) Program of UMGCC is to reduce morbidity and mortality from cancers of hormone-responsive tissues. To achieve this mission, the program focuses on three specific themes and related aims: Theme 1: Therapeutic strategies against hormone-responsive tumors?identify new agents to target malignancies that remain responsive to hormone manipulation; Theme 2: Mechanisms of innate and acquired hormone resistance?identify and target the mechanisms that confer de novo or acquired resistance to hormone manipulation; and Theme 3: Invasion and metastasis? identify the mechanisms that promote tumor dissemination and identify therapeutic strategies to target these mechanisms. The HRC Program has 47 members representing 16 academic departments and 5 schools/colleges of the University of Maryland. Members of the program conduct cancer-focused research that receives $7.1 million total annual funding, including $3.4 million from NCI and $2.6 million from other peer-reviewed sources. In addition, HRC Program members receive over $1 million annually from non-peer-reviewed funding sources. Between January 2010 and December 2014, HRC members authored 407 cancer-related publications, of which 30 percent resulted from intraprogrammatic and 23 percent from interprogrammatic collaborations. Twenty-two percent of the publications represent collaborations with external investigators. Research efforts of HRC faculty are supported by extensive use of the BSS, FCSS, GSS, ISS, PBSS, and TLSS.

View original record on NIH RePORTER →